Actinogen Medical Limited has released a press release.
ACW third positive XanaMIA trial data committee review
Earlier from Actinogen Medical
- Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
- Actinogen receives positive scientific advice from EMA
- Correction-March2026 quarterly activity report & Appendix 4C
- Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update